Inventiva ADR

Loading quotes...

Forecast

The analysts' average price target is €12.52 (+273.73%). The median is €12.52 (+273.73%).

Buy	8
Hold	0
Sell	1

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, Inventiva ADR had revenue of €1.31M and net profit of -€70.4M

(EUR)	June 2026	YoY
Revenue	1.31M	-
Gross profit	847K	-
Net profit	-70.4M	-
EBITDA	-70.71M	-

Fundamentals

Metric	Value
Market capitalization	€169.68M
Number of shares	51.98M
52-week high/low	€6.52 - €2.52
Dividends	No
Beta	0.91
P/E ratio	-6.00
PEG ratio	-0.04
P/B ratio	14.75
P/S ratio	15,330.24

Company profile

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.